跳至主要内容
临床试验/DRKS00032513
DRKS00032513进行中(未招募)不适用

A real-world analysis of adherence barriers and reasons for non-persistence in patients receiving intravitreal therapy with anti- vascular endothelial growth factor therapy –a patient and physician survey in germany

F. Hoffmann-La Roche Ltd0 个研究点目标入组 55 人开始时间: 2023年10月26日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
55

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • The patient has been diagnosed with nAMD and/or DME
  • The patient is at least 18 years of age (DME)/ the patient is at least 50 years of age (nAMD)
  • The patient has started IVT with anti-VEGF therapy in routine clinical practice =5 years ago
  • The patient is currently receiving (or received at the time of last injection) an anti-VEGF agent approved in Germany for the respective indication (nAMD/DME)
  • The patient receives all care in relation to their eye disease at one center/practice (no referral by another practice/center)
  • To the knowledge of the treating physician, the patient has not previously received and is not currently receiving IVT with anti-VEGF therapy at another center/practice
  • The patient is capable of participating in a 45-minute telephone interview in German language
  • Basic clinical information about the patient and his/her care is available in the patient charts (minimum 6-month medical records).

排除标准

  • There are no explicit exclusion criteria.

研究者

相似试验